Aerie Pharma downgraded by Needham
$AERI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Needham downgraded Aerie Pharma from Buy to Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/29/2022 | $14.00 → $15.25 | Buy → Neutral | Citigroup |
| 8/23/2022 | Buy → Hold | Needham | |
| 8/23/2022 | $30.00 → $15.25 | Overweight → Neutral | Cantor Fitzgerald |
| 2/25/2022 | $22.00 → $14.00 | Buy | Needham |
| 11/5/2021 | $24.00 → $22.00 | Buy | Needham |
| 8/5/2021 | $26.00 → $24.00 | Buy | Needham |